GILD vs. SMMT: Gilead Sciences vs. Summit Therapeutics Stock Comparison
How do Gilead Sciences (GILD) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Gilead Sciences (GILD) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | GILD | SMMT |
|---|---|---|
| Name | Gilead Sciences Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 207.00 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 22, 1992 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GILD | SMMT |
|---|---|---|
| Total Return (1Y) | 45.69% | -2.48% |
| Total Return (3Y, Annualized) | 35.30% | 116.18% |
| Total Return (5Y, Annualized) | 25.00% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Gilead Sciences (GILD) has a non-negative beta of 0.36.
| Metric | GILD | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 27.57% | 75.06% |
| Beta (5Y) | 0.36 | -1.51 |
| Max Drawdown (5Y) | -26.59% | -87.64% |
| Avg. Volume (3M) | 5.98M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GILD | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.50 | -0.09 |
| Sortino Ratio (1Y) | 2.48 | -0.13 |
Profitability
ROE (TTM)
Both Gilead Sciences (GILD) at -22.45% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-22.45%
- Max
- 109.18%
- Q3
- 6.23%
- GILD
- -22.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.46%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- GILD
- -12.46%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Gilead Sciences (GILD) at 42.43% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
42.43%
- Max
- 83.12%
- GILD
- 42.43%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GILD | SMMT |
|---|---|---|
| ROE (TTM) | -22.45% | -220.01% |
| ROA (TTM) | 13.47% | -111.99% |
| Net Margin (TTM) | -12.46% | 0.00% |
| Operating Margin (TTM) | 42.43% | 0.00% |
| Gross Margin (TTM) | 79.95% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Gilead Sciences (GILD) reports revenue growth of 2.39%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.
Growth Metrics
| Metric | GILD | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 2.39% | -- |
| Revenue Growth (3Y CAGR) | 2.57% | -- |
| EPS Growth (YoY) | 1,684.21% | -- |
| EPS Growth (3Y CAGR) | 23.04% | -- |
Financial Strength
Current Ratio (MRQ)
Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GILD
- 1.38
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Summit Therapeutics (SMMT) at 0.04 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.02
- GILD
- 2.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GILD | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 1.38 | 5.99 |
| Debt / Equity (MRQ) | 2.02 | 0.04 |
| Net Debt / EBITDA | 1.25 | -- |
Dividends
Dividend Yield (TTM)
Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- GILD
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Summit Therapeutics (SMMT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.46%
- GILD
- 43.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GILD | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 43.46% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Gilead Sciences (GILD) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- GILD
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Gilead Sciences (GILD), whose P/S ratio of 6.68 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- GILD
- 6.68
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Measured against book value, both Gilead Sciences (GILD) at 15.88 and Summit Therapeutics (SMMT) at 23.13 look expensive — each P/B ratio sits above its industry’s benchmark range.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.88
- GILD
- 15.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GILD | SMMT |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 6.68 | -- |
| P/B Ratio (MRQ) | 15.88 | 23.13 |
| Free Cash Flow Yield (TTM) | 5.16% | -1.64% |